Targeted Probiotics Against Bacterial-Fungal Biofilms: A New Concept Seems to Bring Us Closer to Microbiome-modulating Therapy for Inflammatory Bowel Disease

Stanislav Sitkin; Juris Pokrotnieks

doi:10.1093/ibd/izad209

Targeted Probiotics Against Bacterial-Fungal Biofilms: A New Concept Seems to Bring Us Closer to Microbiome-modulating Therapy for Inflammatory Bowel Disease

Inflamm Bowel Dis. 2023 Nov 2;29(11):e40-e41. doi: 10.1093/ibd/izad209.

Authors

Stanislav Sitkin^{1

2

3}, Juris Pokrotnieks^{4

5}

Affiliations

¹ Institute of Perinatology and Pediatrics, Almazov National Medical Research Centre, St. Petersburg, Russia.
² Department of Internal Diseases, Gastroenterology and Dietetics, North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia.
³ Research and Development Department, Elpis Ltd., Riga, Latvia.
⁴ Department of Internal Diseases, Rīga Stradiņš University, Riga, Latvia.
⁵ Centre of Gastroenterology, Hepatology and Nutrition, Pauls Stradiņš Clinical University Hospital, Riga, Latvia.

PMID: 37672357
DOI: 10.1093/ibd/izad209

No abstract available

Keywords: Crohn’s disease; dysbiosis; gut microbiome; inflammatory bowel disease; polymicrobial biofilm; probiotic.

Plain language summary

This article describes the concept of microbiome-modulating therapy for inflammatory bowel diseases using targeted probiotics. A designed probiotic composition is discussed as an example, the targets for which are polymicrobial bacterial-fungal biofilms specific for Crohn’s disease.

Publication types

Editorial
Comment

MeSH terms

Biofilms
Humans
Inflammatory Bowel Diseases* / therapy
Microbiota*
Probiotics*